ENZASTAURIN AND FRAGILE HISTIDINE TRIAD (FHIT)-INCREASING AGENTS FOR THE TREATMENT OF PULMONARY HYPERTENSION

摘要

The present invention provides methods for treatment or prevention ofpulmonary hypertension and emphysema usingagents that increase activity of FHIT, such as Enzastaurin. Included aremethods for using levels of FHIT and/or BMPR2, and checkingfor mutations in FHIT and/or BMPR2, to select patients for treatment or tomonitor effectiveness of treatment. The invention is basedon evidence that by Enzastaurin prevents and reverses pulmonary hypertensioninduced in animal model systems, and that it acts byup-regulation of FHIT and/or BMPR2.